Whitepaper: From molecule to milestone An integrated, phase-appropriate approach to de-risking early-phase drug substance development

Early-phase drug substance development presents significant technical and commercial challenges. Drawing on Onyx Scientific’s experience as a small molecule CDMO, this whitepaper explores how a phase-appropriate, integrated approach to process chemistry, analytical development and solid state science can help reduce risk, improve efficiency and support successful progression from lead optimisation through to clinical manufacture.

Download the whitepaper to discover practical strategies for overcoming common development pitfalls, improving cross-functional collaboration and building more robust drug substance development programmes.

Your name ^*

Your name ^*

Email

Email

By accepting, you consent to being contacted by Onyx Scientific and for your data to be stored. Read our privacy policy here.

Submit